CoChat
Sign Up
Cited by 2,844

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

2023 ESC Guidelines for the management of cardiomyopathies

Arbelo, Elena, Protonotarios, Alexandros, Gimeno, Juan R, Arbustini, Eloisa, Barriales-Villa, Roberto, Basso, Cristina, Bezzina, Connie R, Biagini, Elena, Blom, Nico A, de Boer, Rudolf A, De Winter, Tim, Elliott, Perry M, Flather, Marcus, Garcia-Pavia, Pablo, Haugaa, Kristina H, Ingles, Jodie, Jurcut, Ruxandra Oana, Klaassen, Sabine, Limongelli, Giuseppe, Loeys, Bart, Mogensen, Jens, Olivotto, Iacopo, Pantazis, Antonis, Sharma, Sanjay, Van Tintelen, J Peter, Ware, James S, Kaski, Juan Pablo, ESC Scientific Document Group, Charron, Philippe, Imazio, Massimo, Abdelhamid, Magdy, Aboyans, Victor, Arad, Michael, Asselbergs, Folkert W, Asteggiano, Riccardo, Bilinska, Zofia, Bonnet, Damien, Bundgaard, Henning, Cardim, Nuno Miguel, Čelutkienė, Jelena, Cikes, Maja, De Ferrari, Gaetano Maria, Dusi, Veronica, Falk, Volkmar, Fauchier, Laurent, Gandjbakhch, Estelle, Heliö, Tiina, Koskinas, Konstantinos, Kotecha, Dipak, Landmesser, Ulf, Lazaros, George, Lewis, Basil S, Linhart, Ales, Løchen, Maja-Lisa, Meder, Benjamin, Mindham, Richard, Moon, James, Nielsen, Jens Cosedis, Petersen, Steffen, Prescott, Eva, Sheppard, Mary N, Sinagra, Gianfranco, Sitges, Marta, Tfelt-Hansen, Jacob, Touyz, Rhian, Veltrop, Rogier, Veselka, Josef, Wahbi, Karim, Wilde, Arthur, Zeppenfeld, Katja, Kichou, Brahim, Sisakian, Hamayak, Scherr, Daniel, Gerber, Bernhard, Džubur, Alen, Gospodinova, Mariana, Planinc, Ivo, Moustra, Hera Heracleous, Zemánek, David, Jensen, Morten Steen Kvistholm, Samir, Ahmad, Palm, Kairit, Heliö, Tiina, Wahbi, Karim, Schulze-Bahr, Eric, Haralambos, Vlachopoulos, Sepp, Róbert, Aðalsteinsdóttir, Berglind, Ward, Deirdre, Blich, Miry, Sinagra, Gianfranco, Poniku, Afrim, Lunegova, Olga, Rudzitis, Ainars, Kassab, Roland, Barysienė, Jūratė, Huijnen, Steve, Felice, Tiziana, Vataman, Eleonora, Pavlovic, Nikola, Doghmi, Nawal, Asselbergs, Folkert W, Kostovska, Elizabeta Srbinovska, Almaas, Vibeke Marie, Biernacka, Elżbieta Katarzyna, Brito, Dulce, Rosca, Monica, Zavatta, Marco, Ristic, Arsen, Goncalvesová, Eva, Šinkovec, Matjaž, Cañadas-Godoy, Victoria, Platonov, Pyotr G, Saguner, Ardan M, Saadi, Ahmad Rasheed Al, Kammoun, Ikram, Celik, Ahmet, Nesukay, Elena, Abdullaev, Timur, Prescott, Eva, James, Stefan, Arbelo, Elena, Baigent, Colin, Borger, Michael A, Buccheri, Sergio, Ibanez, Borja, Køber, Lars, Koskinas, Konstantinos C, McEvoy, John William, Mihaylova, Borislava, Mindham, Richard, Neubeck, Lis, Nielsen, Jens Cosedis, Pasquet, Agnes, Rakisheva, Amina, Rocca, Bianca, Rossello, Xavier, Vaartjes, Ilonca, Vrints, Christiaan, Witkowski, Adam, Zeppenfeld, Katja·2023·European Heart Journal
DOI 10.1093/eurheartj/ehad194
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehad194

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both the 2024 ACC/AHA and 2023 ESC guidelines give non-dihydropyridine calcium channel blockers a class I recommendation for patients in whom beta blockers are ineffective or not well tolerated.

    “Both the 2024 ACC/AHA and 2023 ESC guidelines give non-dihydropyridine CCBs a class I recommendation for patients in whom β blockers are ineffective or not well tolerated (table 2). 1 22”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [1]

    Section 7.1.4.1 says verapamil can be used when beta-blockers are contraindicated or ineffective, and diltiazem should be considered when beta-blockers and verapamil are not tolerated or are contraindicated. The retrieved passages do not establish a Class I recommendation for both drugs, and the diltiazem condition is narrower than the claim states. This verdict addresses only the cited ESC guideline, not the ACC/AHA guideline. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

  • Current ESC and ACC guidelines recommend anti-obstructive therapy (beta-blockers or verapamil) to reduce gradient and symptoms in HOCM.

    “Current guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) recommend anti-obstructive therapy, i.e., beta-blockers or verapamil to reduce gradient and symptoms (6–8).”

    From Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy (2024) · cites this paper as [8]

  • The 2023 ESC guidelines assigned a class 2a recommendation to use cardiac myosin inhibitors in patients with symptomatic hypertrophic cardiomyopathy with left ventricular outflow tract obstruction, in addition to beta blockers or calcium channel blockers or as monotherapy when beta blockers, calcium channel blockers, or disopyramide are not tolerated or contraindicated, before considering septal减少

    “The 2023 ESC guidelines assigned a class 2a recommendation to use of CMIs in patients with symptomatic hypertrophic cardiomyopathy with LVOT obstruction, in addition to β blockers or CCBs or as monotherapy when β blockers, CCBs, or disopyramide are not tolerated or contraindicated, before considering SRT. 1”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [1]

  • US guidelines primarily take a dichotomized, algorithmic approach, whereas the European guidelines advise use of the HCM Risk-SCD calculator.

    “US guidelines primarily take a dichotomized, algorithmic approach, 22 whereas the European guidelines advise use of the HCM Risk-SCD calculator”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [1]

  • The diagnosis of HCM was based on the latest ESC guidelines for the diagnosis and management of hypertrophic cardiomyopathies.

    “The diagnosis of HCM was based on the latest ESC guidelines for the diagnosis and management of hypertrophic cardiomyopathies: patients with familial or genetically diagnosed HCM with wall thickness ≥13 mm in one or more left ventricular myocardial segments or patients with wall thickness ≥15 mm in the absence of any other cause of hypertrophy (7, 8).”

    From Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy (2024) · cites this paper as [8]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1156

  1. Authors/Task Force Members, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  2. Elliott, 2008, Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 29, 270, 10.1093/eurheartj/ehm342 · DOI
  3. Wilde, 2022, European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases, Europace, 24, 1307, 10.1093/europace/euac030 · DOI
  4. Towbin, 2019, 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy, Heart Rhythm, 16, e301, 10.1016/j.hrthm.2019.05.007 · DOI
  5. Corrado, 2020, Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria, Int J Cardiol, 319, 106, 10.1016/j.ijcard.2020.06.005 · DOI
  6. Biesecker, 2021, A dyadic approach to the delineation of diagnostic entities in clinical genomics, Am J Hum Genet, 108, 8, 10.1016/j.ajhg.2020.11.013 · DOI
  7. Arbustini, 2013, The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation, J Am Coll Cardiol, 62, 2046, 10.1016/j.jacc.2013.08.1644 · DOI
  8. Disertori, 2013, Autosomal recessive atrial dilated cardiomyopathy with standstill evolution associated with mutation of Natriuretic Peptide Precursor A, Circ Cardiovasc Genet, 6, 27, 10.1161/CIRCGENETICS.112.963520 · DOI
  9. Pinto, 2016, Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases, Eur Heart J, 37, 1850, 10.1093/eurheartj/ehv727 · DOI
  10. Marcus, 2010, Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria, Eur Heart J, 31, 806, 10.1093/eurheartj/ehq025 · DOI
  11. Rapezzi, 2022, Restrictive cardiomyopathy: definition and diagnosis, Eur Heart J, 43, 4679, 10.1093/eurheartj/ehac543 · DOI
  12. van Waning, 2019, Cardiac phenotypes, genetics, and risks in familial noncompaction cardiomyopathy, J Am Coll Cardiol, 73, 1601, 10.1016/j.jacc.2018.12.085 · DOI
  13. Sedaghat-Hamedani, 2017, Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy, Eur Heart J, 38, 3449, 10.1093/eurheartj/ehx545 · DOI
  14. Klaassen, 2008, Mutations in sarcomere protein genes in left ventricular noncompaction, Circulation, 117, 2893, 10.1161/CIRCULATIONAHA.107.746164 · DOI
  15. Probst, 2011, Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype, Circ Cardiovasc Genet, 4, 367, 10.1161/CIRCGENETICS.110.959270 · DOI
  16. Hoedemaekers, 2010, The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy, Circ Cardiovasc Genet, 3, 232, 10.1161/CIRCGENETICS.109.903898 · DOI
  17. Gati, 2014, Reversible de novo left ventricular trabeculations in pregnant women: implications for the diagnosis of left ventricular noncompaction in low-risk populations, Circulation, 130, 475, 10.1161/CIRCULATIONAHA.114.008554 · DOI
  18. Gati, 2013, Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes?, Heart, 99, 401, 10.1136/heartjnl-2012-303418 · DOI
  19. de la Chica, 2020, Association between left ventricular noncompaction and vigorous physical activity, J Am Coll Cardiol, 76, 1723, 10.1016/j.jacc.2020.08.030 · DOI
  20. Jensen, 2017, Excessive trabeculations in noncompaction do not have the embryonic identity, Int J Cardiol, 227, 325, 10.1016/j.ijcard.2016.11.089 · DOI
  21. Faber, 2021, Lack of morphometric evidence for ventricular compaction in humans, J Cardiol, 78, 397, 10.1016/j.jjcc.2021.03.006 · DOI
  22. Anderson, 2017, Key questions relating to left ventricular noncompaction cardiomyopathy: is the emperor still wearing any clothes?, Can J Cardiol, 33, 747
  23. Lyon, 2016, Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 18, 8, 10.1002/ejhf.424 · DOI
  24. McKenna, 2017, Classification, epidemiology, and global burden of cardiomyopathies, Circ Res, 121, 722, 10.1161/CIRCRESAHA.117.309711 · DOI
  25. Hershberger, 2013, Dilated cardiomyopathy: the complexity of a diverse genetic architecture, Nat Rev Cardiol, 10, 531, 10.1038/nrcardio.2013.105 · DOI
  26. Hada, 1987, Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening, Am J Cardiol, 59, 183, 10.1016/S0002-9149(87)80107-8 · DOI
  27. Agnarsson, 1992, The prevalence of hypertrophic cardiomyopathy in men: an echocardiographic population screening study with a review of death records, J Intern Med, 232, 499, 10.1111/j.1365-2796.1992.tb00623.x · DOI
  28. Maron, 1995, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults, Circulation, 92, 785, 10.1161/01.CIR.92.4.785 · DOI
  29. Maron, 1999, Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities, J Am Coll Cardiol, 33, 1590, 10.1016/S0735-1097(99)00039-X · DOI
  30. Maron, 2004, Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study), Am J Cardiol, 93, 1510, 10.1016/j.amjcard.2004.03.007 · DOI
  31. Zou, 2004, Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults, Am J Med, 116, 14, 10.1016/j.amjmed.2003.05.009 · DOI
  32. Maro, 2006, Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania, Trop Doct, 36, 225, 10.1258/004947506778604904 · DOI
  33. Basavarajaiah, 2008, Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening, J Am Coll Cardiol, 51, 1033, 10.1016/j.jacc.2007.10.055 · DOI
  34. Nugent, 2003, The epidemiology of childhood cardiomyopathy in Australia, N Engl J Med, 348, 1639, 10.1056/NEJMoa021737 · DOI
  35. Lipshultz, 2003, The incidence of pediatric cardiomyopathy in two regions of the United States, N Engl J Med, 348, 1647, 10.1056/NEJMoa021715 · DOI
  36. Arola, 1997, Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland, Am J Epidemiol, 146, 385, 10.1093/oxfordjournals.aje.a009291 · DOI
  37. Codd, 1989, Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984, Circulation, 80, 564, 10.1161/01.CIR.80.3.564 · DOI
  38. Andrews, 2008, New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland, Circulation, 117, 79, 10.1161/CIRCULATIONAHA.106.671735 · DOI
  39. Peters, 2004, Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital, Int J Cardiol, 97, 499, 10.1016/j.ijcard.2003.10.037 · DOI
  40. Corrado, 2006, Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program, JAMA, 296, 1593, 10.1001/jama.296.13.1593 · DOI · Paper page
  41. Migliore, 2012, Prevalence of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave inversion at preparticipation screening, Circulation, 125, 529, 10.1161/CIRCULATIONAHA.111.055673 · DOI
  42. Ware, 2018, Genetic etiology for alcohol-induced cardiac toxicity, J Am Coll Cardiol, 71, 2293, 10.1016/j.jacc.2018.03.462 · DOI
  43. Garcia-Pavia, 2019, Genetic variants associated with cancer therapy-induced cardiomyopathy, Circulation, 140, 31, 10.1161/CIRCULATIONAHA.118.037934 · DOI
  44. Ware, 2016, Shared genetic predisposition in peripartum and dilated cardiomyopathies, N Engl J Med, 374, 233, 10.1056/NEJMoa1505517 · DOI
  45. Goli, 2021, Genetic and phenotypic landscape of peripartum cardiomyopathy, Circulation, 143, 1852, 10.1161/CIRCULATIONAHA.120.052395 · DOI
  46. Doheny, 2018, Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995–2017, J Med Genet, 55, 261, 10.1136/jmedgenet-2017-105080 · DOI
  47. Tini, 2021, Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: methodological issues and clinical implications, Eur J Clin Invest, 51, e13665, 10.1111/eci.13665 · DOI
  48. Aimo, 2022, Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies, Eur J Heart Fail, 24, 2342, 10.1002/ejhf.2532 · DOI
  49. Tiron, 2022, Prevalence of pathogenic variants in cardiomyopathy-associated genes in myocarditis, Circ Genom Precis Med, 15, e003408, 10.1161/CIRCGEN.121.003408 · DOI
  50. Seidel, 2021, Pathogenic variants associated with dilated cardiomyopathy predict outcome in pediatric myocarditis, Circ Genom Precis Med, 14, e003250, 10.1161/CIRCGEN.120.003250 · DOI
  51. Ammirati, 2022, Acute myocarditis associated with desmosomal gene variants, JACC Heart Fail, 10, 714, 10.1016/j.jchf.2022.06.013 · DOI · Paper page
  52. Cardim, 2011, From hypertrophic cardiomyopathy centers to inherited cardiovascular disease centers in Europe. A small or a major step? A position paper from the Nucleus of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology, Rev Port Cardiol, 30, 829, 10.1016/j.repc.2011.09.005 · DOI
  53. Barriales-Villa, 2016, Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms, Rev Esp Cardiol, 69, 300, 10.1016/j.recesp.2015.11.031 · DOI
  54. Vriz, 2021, A complex unit for a complex disease: the HCM-Family Unit, Monaldi Arch Chest Dis, 92
  55. Basso, 2017, Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology, Virchows Arch, 471, 691, 10.1007/s00428-017-2221-0 · DOI
  56. Fellmann, 2019, European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death, Eur J Hum Genet, 27, 1763, 10.1038/s41431-019-0445-y · DOI
  57. de Hosson, 2021, Needs and experiences of adolescents with congenital heart disease and parents in the transitional process: a qualitative study, J Pediatr Nurs, 61, 90, 10.1016/j.pedn.2021.03.016 · DOI
  58. de Hosson, 2020, Development of a transition program for adolescents with congenital heart disease, Eur J Pediatr, 179, 339, 10.1007/s00431-019-03515-4 · DOI
  59. Tini, 2020, Telehealth monitoring for hypertrophic cardiomyopathy and amyloid cardiomyopathy patients: lessons from the coronavirus disease 2019 lockdown in Italy, J Cardiovasc Med, 21, 622, 10.2459/JCM.0000000000001024 · DOI
  60. Rapezzi, 2013, Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 34, 1448, 10.1093/eurheartj/ehs397 · DOI
  61. Elliott, 2016, European cardiomyopathy pilot registry: EURObservational research programme of the European Society of Cardiology, Eur Heart J, 37, 164, 10.1093/eurheartj/ehv497 · DOI
  62. van Velzen, 2018, Outcomes of contemporary family screening in hypertrophic cardiomyopathy, Circ Genom Precis Med, 11, e001896, 10.1161/CIRCGEN.117.001896 · DOI · Paper page
  63. Ranthe, 2015, Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons, Circulation, 132, 1013, 10.1161/CIRCULATIONAHA.114.013478 · DOI
  64. Gimeno, 2009, Penetrance and risk profile in inherited cardiac diseases studied in a dedicated screening clinic, Am J Cardiol, 104, 406, 10.1016/j.amjcard.2009.03.055 · DOI
  65. Ploski, 2016, Evidence for troponin C (TNNC1) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome in infancy, Am J Med Genet A, 170, 3241, 10.1002/ajmg.a.37860 · DOI
  66. Surmacz, 2018, Autosomal recessive transmission of familial nonsyndromic dilated cardiomyopathy due to compound desmoplakin gene mutations, Pol Arch Intern Med, 128, 785
  67. McDonagh, 2021, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, 42, 3599, 10.1093/eurheartj/ehab368 · DOI · Paper page
  68. McDonagh, 2023, 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, 44, 3627, 10.1093/eurheartj/ehad195 · DOI · Paper page
  69. Bonny, 2010, C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia, Cardiol Res Pract, 2010, 919783, 10.4061/2010/919783 · DOI
  70. Donal, 2019, Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 20, 1075, 10.1093/ehjci/jez178 · DOI
  71. Haugaa, 2017, Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy–an expert consensus document of the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 18, 237, 10.1093/ehjci/jew229 · DOI
  72. Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 16, 233, 10.1093/ehjci/jev014 · DOI
  73. Lancellotti, 2013, Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography, Eur Heart J Cardiovasc Imaging, 14, 721, 10.1093/ehjci/jet123 · DOI
  74. Charron, 2010, Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 31, 2715, 10.1093/eurheartj/ehq271 · DOI
  75. Liu, 2016, Longitudinal strain bull’s eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy, Eur J Med Res, 21, 21, 10.1186/s40001-016-0216-y · DOI
  76. Haugaa, 2015, Mechanical dispersion by strain echocardiography: a predictor of ventricular arrhythmias in subjects with lamin A/C mutations, JACC Cardiovasc Imaging, 8, 104, 10.1016/j.jcmg.2014.04.029 · DOI
  77. Haugaa, 2012, Risk assessment of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy by strain echocardiography, J Am Soc Echocardiogr, 25, 667, 10.1016/j.echo.2012.02.004 · DOI
  78. Leren, 2017, Combination of ECG and echocardiography for identification of arrhythmic events in early ARVC, JACC Cardiovasc Imaging, 10, 503, 10.1016/j.jcmg.2016.06.011 · DOI
  79. Haland, 2016, Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy, Eur Heart J Cardiovasc Imaging, 17, 613, 10.1093/ehjci/jew005 · DOI
  80. Norrish, 2019, Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids), JAMA Cardiol, 4, 918, 10.1001/jamacardio.2019.2861 · DOI
  81. Lopez, 2021, Pediatric heart network echocardiographic Z scores: comparison with other published models, J Am Soc Echocardiogr, 34, 185, 10.1016/j.echo.2020.09.019 · DOI
  82. Adabag, 2006, Determinants for clinical diagnosis of hypertrophic cardiomyopathy, Am J Cardiol, 98, 1507, 10.1016/j.amjcard.2006.07.029 · DOI
  83. Klues, 1995, Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients, J Am Coll Cardiol, 26, 1699, 10.1016/0735-1097(95)00390-8 · DOI
  84. Shapiro, 1983, Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study, J Am Coll Cardiol, 2, 437, 10.1016/S0735-1097(83)80269-1 · DOI
  85. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  86. Nistri, 2006, Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy), Am J Cardiol, 98, 960, 10.1016/j.amjcard.2006.05.013 · DOI
  87. Debonnaire, 2017, Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation, Circ Arrhythm Electrophysiol, 10, e004052, 10.1161/CIRCEP.116.004052 · DOI
  88. Harris, 2006, Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, 114, 216, 10.1161/CIRCULATIONAHA.105.583500 · DOI
  89. Alba, 2020, Prognostic value of late gadolinium enhancement for the prediction of cardiovascular outcomes in dilated cardiomyopathy: an international, multi-institutional study of the MINICOR group, Circ Cardiovasc Imaging, 13, e010105, 10.1161/CIRCIMAGING.119.010105 · DOI
  90. Leong, 2012, Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography, Eur Heart J, 33, 640, 10.1093/eurheartj/ehr391 · DOI
  91. Yoerger, 2005, Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia, J Am Coll Cardiol, 45, 860, 10.1016/j.jacc.2004.10.070 · DOI
  92. Pieles, 2019, Association of echocardiographic parameters of right ventricular remodeling and myocardial performance with modified task force criteria in adolescents with arrhythmogenic right ventricular cardiomyopathy, Circ Cardiovasc Imaging, 12, e007693, 10.1161/CIRCIMAGING.118.007693 · DOI
  93. Mehta, 2008, Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing, Chest, 133, 1426, 10.1378/chest.07-2784 · DOI
  94. Skold, 2002, Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography, J Intern Med, 252, 465, 10.1046/j.1365-2796.2002.01058.x · DOI
  95. Joyce, 2015, Subclinical left ventricular dysfunction by echocardiographic speckle–tracking strain analysis relates to outcome in sarcoidosis, Eur J Heart Fail, 17, 51, 10.1002/ejhf.205 · DOI
  96. Pagourelias, 2017, Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters, Circ Cardiovasc Imaging, 10, e005588, 10.1161/CIRCIMAGING.116.005588 · DOI
  97. Phelan, 2012, Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis, Heart, 98, 1442, 10.1136/heartjnl-2012-302353 · DOI
  98. Linhart, 2007, Cardiac manifestations of Anderson–Fabry disease: results from the international Fabry outcome survey, Eur Heart J, 28, 1228, 10.1093/eurheartj/ehm153 · DOI
  99. Boldrini, 2020, Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis, JACC Cardiovasc Imaging, 13, 909, 10.1016/j.jcmg.2019.10.011 · DOI
  100. Pieroni, 2006, Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization, J Am Coll Cardiol, 47, 1663, 10.1016/j.jacc.2005.11.070 · DOI
  101. Zemrak, 2014, The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study, J Am Coll Cardiol, 64, 1971, 10.1016/j.jacc.2014.08.035 · DOI
  102. Steeden, 2020, Rapid whole-heart CMR with single volume super-resolution, J Cardiovasc Magn Reson, 22, 56, 10.1186/s12968-020-00651-x · DOI
  103. Kiblboeck, 2018, Artefacts in 1.5 Tesla and 3 Tesla cardiovascular magnetic resonance imaging in patients with leadless cardiac pacemakers, J Cardiovasc Magn Reson, 20, 47, 10.1186/s12968-018-0469-4 · DOI
  104. Rajiah, 2020, Cardiac magnetic resonance in patients with cardiac implantable electronic devices: challenges and solutions, J Thorac Imaging, 35, W1, 10.1097/RTI.0000000000000462 · DOI
  105. Gandjbakhch, 2020, Joint Position Paper of the Working Group of Pacing and Electrophysiology of the French Society of Cardiology and the French Society of Diagnostic and Interventional Cardiac and Vascular Imaging on magnetic resonance imaging in patients with cardiac electronic implantable devices, Arch Cardiovasc Dis, 113, 473, 10.1016/j.acvd.2020.03.015 · DOI
  106. Nazarian, 2017, Safety of magnetic resonance imaging in patients with cardiac devices, N Engl J Med, 377, 2555, 10.1056/NEJMoa1604267 · DOI
  107. Russo, 2017, Assessing the risks associated with MRI in patients with a pacemaker or defibrillator, N Engl J Med, 376, 755, 10.1056/NEJMoa1603265 · DOI
  108. Gakenheimer-Smith, 2020, MRI in pediatric and congenital heart disease patients with CIEDs and epicardial or abandoned leads, Pacing Clin Electrophysiol, 43, 797, 10.1111/pace.13984 · DOI
  109. Vigen, 2021, Recommendations for imaging patients with cardiac implantable electronic devices (CIEDs), J Magn Reson Imaging, 53, 1311, 10.1002/jmri.27320 · DOI
  110. Bhuva, 2019, MRI for patients with cardiac implantable electronic devices: simplifying complexity with a ‘one-stop’ service model, BMJ Qual Saf, 28, 853, 10.1136/bmjqs-2018-009079 · DOI
  111. Seewoster, 2019, Cardiovascular magnetic resonance imaging in patients with cardiac implantable electronic devices: best practice and real-world experience, Europace, 21, 1220, 10.1093/europace/euz112 · DOI
  112. Stühlinger, 2022, EHRA consensus on prevention and management of interference due to medical procedures in patients with cardiac implantable electronic devices, Europace, 24, 1512, 10.1093/europace/euac040 · DOI
  113. Primary, 2021, 2021 Update on safety of magnetic resonance imaging: joint statement from Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society, Can J Cardiol, 37, 835
  114. Messroghli, 2017, Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI), J Cardiovasc Magn Reson, 19, 75, 10.1186/s12968-017-0389-8 · DOI
  115. Baggiano, 2020, Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis, JACC Cardiovasc Imaging, 13, 69, 10.1016/j.jcmg.2019.03.026 · DOI
  116. Nordin, 2019, Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy, Circ Cardiovasc Imaging, 12, e009430, 10.1161/CIRCIMAGING.119.009430 · DOI
  117. Ray, 2016, Association between MRI exposure during pregnancy and fetal and childhood outcomes, JAMA, 316, 952, 10.1001/jama.2016.12126 · DOI
  118. Andreini, 2020, CMR for identifying the substrate of ventricular arrhythmia in patients with normal echocardiography, JACC Cardiovasc Imaging, 13, 410, 10.1016/j.jcmg.2019.04.023 · DOI
  119. Halliday, 2019, Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement, JACC Cardiovasc Imaging, 12, 1645, 10.1016/j.jcmg.2018.07.015 · DOI
  120. Barison, 2018, Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy, Int J Cardiol, 250, 195, 10.1016/j.ijcard.2017.10.043 · DOI
  121. Holmstrom, 2011, Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy, J Cardiovasc Magn Reson, 13, 30, 10.1186/1532-429X-13-30 · DOI
  122. Olivotto, 2008, Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy, J Am Coll Cardiol, 52, 559, 10.1016/j.jacc.2008.04.047 · DOI
  123. Neubauer, 2019, Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry, J Am Coll Cardiol, 74, 2333, 10.1016/j.jacc.2019.08.1057 · DOI
  124. Miller, 2019, Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging, PLoS One, 14, e0217612, 10.1371/journal.pone.0217612 · DOI
  125. Quarta, 2013, Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular magnetic resonance, J Cardiovasc Magn Reson, 15, 16, 10.1186/1532-429X-15-16 · DOI
  126. Menghetti, 1996, Spin-echo nuclear magnetic resonance for tissue characterisation in arrhythmogenic right ventricular cardiomyopathy, Heart, 76, 467, 10.1136/hrt.76.6.467 · DOI
  127. Sen-Chowdhry, 2007, Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression, Circulation, 115, 1710, 10.1161/CIRCULATIONAHA.106.660241 · DOI
  128. Aquaro, 2016, Usefulness of combined functional assessment by cardiac magnetic resonance and tissue characterization versus task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy, Am J Cardiol, 118, 1730, 10.1016/j.amjcard.2016.08.056 · DOI
  129. Petersen, 2005, Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging, J Am Coll Cardiol, 46, 101, 10.1016/j.jacc.2005.03.045 · DOI
  130. Masso, 2020, Left ventricular noncompaction detected by cardiac magnetic resonance screening: a reexamination of diagnostic criteria, Tex Heart Inst J, 47, 183, 10.14503/THIJ-19-7157 · DOI
  131. Grothoff, 2012, Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies, Eur Radiol, 22, 2699, 10.1007/s00330-012-2554-7 · DOI
  132. Jacquier, 2010, Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction, Eur Heart J, 31, 1098, 10.1093/eurheartj/ehp595 · DOI
  133. Sado, 2013, Identification and assessment of Anderson–Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping, Circ Cardiovasc Imaging, 6, 392, 10.1161/CIRCIMAGING.112.000070 · DOI
  134. Deva, 2016, Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson–Fabry disease, J Cardiovasc Magn Reson, 18, 14, 10.1186/s12968-016-0233-6 · DOI
  135. Francone, 2014, Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance, ISRN Radiol, 2014, 365404, 10.1155/2014/365404 · DOI
  136. Di Marco, 2017, Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis, JACC Heart Fail, 5, 28, 10.1016/j.jchf.2016.09.017 · DOI
  137. Klem, 2021, Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy, Circulation, 143, 1343, 10.1161/CIRCULATIONAHA.120.048477 · DOI
  138. Rastegar, 2016, Fibrofatty changes: incidence at cardiac MR imaging in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy, Radiology, 280, 405, 10.1148/radiol.2016150988 · DOI
  139. te Riele, 2013, Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers, J Am Coll Cardiol, 62, 1761, 10.1016/j.jacc.2012.11.087 · DOI
  140. Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 · DOI · Paper page
  141. He, 2018, Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy, Heart Lung, 47, 122, 10.1016/j.hrtlng.2017.10.008 · DOI
  142. Weissler-Snir, 2021, Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy–are there predictors of appropriate therapy?, Heart Rhythm, 18, 63, 10.1016/j.hrthm.2020.08.009 · DOI
  143. Raman, 2019, Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications, Eur Heart J Cardiovasc Imaging, 20, 157, 10.1093/ehjci/jey135 · DOI
  144. Ho, 2013, T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy, Circ Cardiovasc Imaging, 6, 415, 10.1161/CIRCIMAGING.112.000333 · DOI
  145. Moon, 2004, Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography, Heart, 90, 645, 10.1136/hrt.2003.014969 · DOI
  146. Aquaro, 2020, Prognostic value of magnetic resonance phenotype in patients with arrhythmogenic right ventricular cardiomyopathy, J Am Coll Cardiol, 75, 2753, 10.1016/j.jacc.2020.04.023 · DOI
  147. Martinez-Naharro, 2018, CMR-verified regression of cardiac AL amyloid after chemotherapy, JACC Cardiovasc Imaging, 11, 152, 10.1016/j.jcmg.2017.02.012 · DOI
  148. Fontana, 2021, Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression, JACC Cardiovasc Imaging, 14, 189, 10.1016/j.jcmg.2020.07.043 · DOI
  149. Martinez-Naharro, 2019, Native T1 and extracellular volume in transthyretin amyloidosis, JACC Cardiovasc Imaging, 12, 810, 10.1016/j.jcmg.2018.02.006 · DOI
  150. Puntmann, 2017, T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis, Radiology, 285, 63, 10.1148/radiol.2017162732 · DOI
  151. Pennell, 2012, Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major, Haematologica, 97, 842, 10.3324/haematol.2011.049957 · DOI
  152. Dalal, 2009, Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics–magnetic resonance imaging correlation study, J Am Coll Cardiol, 53, 1289, 10.1016/j.jacc.2008.12.045 · DOI
  153. Stokke, 2020, Absence of ECG Task Force Criteria does not rule out structural changes in genotype positive ARVC patients, Int J Cardiol, 317, 152, 10.1016/j.ijcard.2020.05.095 · DOI
  154. Moon, 2003, Gadolinium enhanced cardiovascular magnetic resonance in Anderson–Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium, Eur Heart J, 24, 2151, 10.1016/j.ehj.2003.09.017 · DOI
  155. Huurman, 2022, Contemporary family screening in hypertrophic cardiomyopathy: the role of cardiovascular magnetic resonance, Eur Heart J Cardiovasc Imaging, 23, 1144, 10.1093/ehjci/jeac099 · DOI
  156. Valente, 2013, Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy, Circ Cardiovasc Genet, 6, 230, 10.1161/CIRCGENETICS.113.000037 · DOI
  157. Germans, 2010, How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance, J Cardiovasc Magn Reson, 12, 13, 10.1186/1532-429X-12-13 · DOI
  158. Germans, 2006, Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations, J Am Coll Cardiol, 48, 2518, 10.1016/j.jacc.2006.08.036 · DOI
  159. Aziz, 2019, Emerging role of cardiac computed tomography in heart failure, ESC Heart Fail, 6, 909, 10.1002/ehf2.12479 · DOI
  160. Galand, 2020, Utility of computed tomography to predict ventricular arrhythmias in patients with nonischemic cardiomyopathy receiving cardiac resynchronization therapy, Am J Cardiol, 125, 607, 10.1016/j.amjcard.2019.11.003 · DOI
  161. Palmisano, 2021, Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with persisting arrhythmias after myocarditis, JACC Cardiovasc Imaging, 14, 288, 10.1016/j.jcmg.2020.03.009 · DOI
  162. Wicks, 2018, Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis, Eur Heart J Cardiovasc Imaging, 19, 757, 10.1093/ehjci/jex340 · DOI
  163. Youssef, 2012, The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience, J Nucl Med, 53, 241, 10.2967/jnumed.111.090662 · DOI
  164. Bravo, 2017, Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies, Heart Fail Rev, 22, 455, 10.1007/s10741-017-9628-1 · DOI
  165. Perugini, 2005, Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy, J Am Coll Cardiol, 46, 1076, 10.1016/j.jacc.2005.05.073 · DOI
  166. Hutt, 2017, Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid, Eur Heart J Cardiovasc Imaging, 18, 1344, 10.1093/ehjci/jew325 · DOI
  167. Gillmore, 2016, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, Circulation, 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 · DOI
  168. Langer, 2014, Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients, Int J Cardiovasc Imaging, 30, 659, 10.1007/s10554-013-0358-8 · DOI
  169. Asferg, 2012, Accuracy of multi-slice computed tomography for measurement of left ventricular ejection fraction compared with cardiac magnetic resonance imaging and two-dimensional transthoracic echocardiography: a systematic review and meta-analysis, Eur J Radiol, 81, e757, 10.1016/j.ejrad.2012.02.002 · DOI
  170. Premaratne, 2017, Using coronary calcification to exclude an ischemic etiology for cardiomyopathy: a validation study and systematic review, Int J Cardiol, 230, 518, 10.1016/j.ijcard.2016.12.068 · DOI
  171. Dweck, 2018, Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis, JACC Cardiovasc Imaging, 11, 94, 10.1016/j.jcmg.2017.02.021 · DOI
  172. Okumura, 2004, Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis, J Nucl Med, 45, 1989
  173. Besler, 2016, Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy, Eur J Heart Fail, 18, 1442, 10.1002/ejhf.579 · DOI
  174. Ardehali, 2004, Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy, Am Heart J, 147, 919, 10.1016/j.ahj.2003.09.020 · DOI
  175. Ardehali, 2005, A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy, Am Heart J, 150, 459, 10.1016/j.ahj.2004.10.006 · DOI
  176. Hahn, 2020, Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis, JACC Heart Fail, 8, 712, 10.1016/j.jchf.2020.04.007 · DOI
  177. Lorenzini, 2020, Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers, J Am Coll Cardiol, 76, 550, 10.1016/j.jacc.2020.06.011 · DOI
  178. Dalal, 2006, Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy, J Am Coll Cardiol, 48, 1416, 10.1016/j.jacc.2006.06.045 · DOI
  179. Claes, 2016, Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers, Eur Heart J, 37, 1815, 10.1093/eurheartj/ehv522 · DOI
  180. James, 2013, Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers, J Am Coll Cardiol, 62, 1290, 10.1016/j.jacc.2013.06.033 · DOI · Paper page
  181. Tadros, 2021, Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect, Nat Genet, 53, 128, 10.1038/s41588-020-00762-2 · DOI
  182. Harper, 2021, Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity, Nat Genet, 53, 135, 10.1038/s41588-020-00764-0 · DOI · Paper page
  183. Pugh, 2014, The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing, Genet Med, 16, 601, 10.1038/gim.2013.204 · DOI
  184. Escobar-Lopez, 2021, Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy, J Am Coll Cardiol, 78, 1682, 10.1016/j.jacc.2021.08.039 · DOI
  185. Gigli, 2019, Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy, J Am Coll Cardiol, 74, 1480, 10.1016/j.jacc.2019.06.072 · DOI
  186. Garnier, 2021, Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23, Eur Heart J, 42, 2000, 10.1093/eurheartj/ehab030 · DOI
  187. Pua, 2020, Genetic studies of hypertrophic cardiomyopathy in Singaporeans identify variants in TNNI3 and TNNT2 that are common in Chinese patients, Circ Genom Precis Med, 13, 424, 10.1161/CIRCGEN.119.002823 · DOI
  188. Jordan, 2021, Evidence-based assessment of genes in dilated cardiomyopathy, Circulation, 144, 7, 10.1161/CIRCULATIONAHA.120.053033 · DOI
  189. Ingles, 2019, Evaluating the clinical validity of hypertrophic cardiomyopathy genes, Circ Genom Precis Med, 12, e002460, 10.1161/CIRCGEN.119.002460 · DOI
  190. Miller, 2021, ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG), Genet Med, 23, 1381, 10.1038/s41436-021-01172-3 · DOI
  191. Miller, 2021, Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG), Genet Med, 23, 1391, 10.1038/s41436-021-01171-4 · DOI · Paper page
  192. Watkins, 2021, Time to think differently about sarcomere-negative hypertrophic cardiomyopathy, Circulation, 143, 2415, 10.1161/CIRCULATIONAHA.121.053527 · DOI
  193. Kumuthini, 2022, The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review, Hum Genet, 141, 1697, 10.1007/s00439-022-02452-x · DOI
  194. Biddinger, 2022, Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a National Biobank, JAMA Cardiol, 7, 715, 10.1001/jamacardio.2022.1061 · DOI
  195. Kelly, 2018, Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel, Genet Med, 20, 351, 10.1038/gim.2017.218 · DOI
  196. Arbustini, 2022, Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics, Eur Heart J, 43, 1901, 10.1093/eurheartj/ehab895 · DOI
  197. National Society of Genetic Counselors Definition Task Force, 2006, A new definition of genetic counseling: National Society of Genetic Counselors’ Task Force report, J Genet Couns, 15, 77, 10.1007/s10897-005-9014-3 · DOI
  198. Biesecker, 2001, Goals of genetic counseling, Clin Genet, 60, 323, 10.1034/j.1399-0004.2001.600501.x · DOI
  199. Ingles, 2011, The emerging role of the cardiac genetic counselor, Heart Rhythm, 8, 1958, 10.1016/j.hrthm.2011.07.017 · DOI
  200. Bordet, 2020, Psychosocial impact of predictive genetic testing in hereditary heart diseases: the PREDICT study, J Clin Med, 9, 1365, 10.3390/jcm9051365 · DOI

200 of 1156 shown

Cited by

Sorted by citations

Metadata

Authors
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., De Winter, T., Elliott, P. M., Flather, M., Garcia-Pavia, P., Haugaa, K. H., Ingles, J., Jurcut, R. O., Klaassen, S., Limongelli, G., Loeys, B., Mogensen, J., Olivotto, I., Pantazis, A., Sharma, S., Van Tintelen, J. P., Ware, J. S., Kaski, J. P., ESC Scientific Document Group, Charron, P., Imazio, M., Abdelhamid, M., Aboyans, V., Arad, M., Asselbergs, F. W., Asteggiano, R., Bilinska, Z., Bonnet, D., Bundgaard, H., Cardim, N. M., Čelutkienė, J., Cikes, M., De Ferrari, G. M., Dusi, V., Falk, V., Fauchier, L., Gandjbakhch, E., Heliö, T., Koskinas, K., Kotecha, D., Landmesser, U., Lazaros, G., Lewis, B. S., Linhart, A., Løchen, M.-L., Meder, B., Mindham, R., Moon, J., Nielsen, J. C., Petersen, S., Prescott, E., Sheppard, M. N., Sinagra, G., Sitges, M., Tfelt-Hansen, J., Touyz, R., Veltrop, R., Veselka, J., Wahbi, K., Wilde, A., Zeppenfeld, K., Kichou, B., Sisakian, H., Scherr, D., Gerber, B., Džubur, A., Gospodinova, M., Planinc, I., Moustra, H. H., Zemánek, D., Jensen, M. S. K., Samir, A., Palm, K., Heliö, T., Wahbi, K., Schulze-Bahr, E., Haralambos, V., Sepp, R., Aðalsteinsdóttir, B., Ward, D., Blich, M., Sinagra, G., Poniku, A., Lunegova, O., Rudzitis, A., Kassab, R., Barysienė, J., Huijnen, S., Felice, T., Vataman, E., Pavlovic, N., Doghmi, N., Asselbergs, F. W., Kostovska, E. S., Almaas, V. M., Biernacka, E. K., Brito, D., Rosca, M., Zavatta, M., Ristic, A., Goncalvesová, E., Šinkovec, M., Cañadas-Godoy, V., Platonov, P. G., Saguner, A. M., Saadi, A. R. A., Kammoun, I., Celik, A., Nesukay, E., Abdullaev, T., Prescott, E., James, S., Arbelo, E., Baigent, C., Borger, M. A., Buccheri, S., Ibanez, B., Køber, L., Koskinas, K. C., McEvoy, J. W., Mihaylova, B., Mindham, R., Neubeck, L., Nielsen, J. C., Pasquet, A., Rakisheva, A., Rocca, B., Rossello, X., Vaartjes, I., Vrints, C., Witkowski, A., & Zeppenfeld, K.
Affiliations
  • (Task Force Co-ordinator) ( )
  • (Italy)
  • (Spain)
  • (Netherlands)
  • (Belgium)
  • (United Kingdom)
  • (Sweden)
  • (Australia)
  • (Romania)
  • (Germany)
  • (Denmark)
  • (Chairperson) ( )
ORCID
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2023-08-25
Volume
44
Issue
37
Pages
3503-3626
ISSN
  • 0195-668X
  • 1522-9645
DOI
10.1093/eurheartj/ehad194
Cited by
2,844
References
50
Language
en
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review